Overview

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Status:
Not yet recruiting
Trial end date:
2024-10-10
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline